Please assess the completion status of the following clinical trial:

Trial Title: Ventavis® Registry Protocol

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Have a current diagnosis of WHO Group I PAH~2. Have initiated therapy with commercial Ventavis® administered via portable nebulizer at least 3 months prior to study enrollment, either with commercial product or from participation in Actelion's Clinical Study AC-063A302~3. Age \> or = 18 years old at the time of enrollment~Exclusion Criteria:~1. Meet the criteria for inclusion into WHO Groups II, III, IV or V PAH~2. Are not currently on commercial Ventavis®~3. Have initiated therapy with commercial Ventavis® administered via portable nebulizer less than 3 months prior to study enrollment

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: None): Patients with WHO Group I pulmonary arterial hypertension (PAH) who have been receiving therapy with Ventavis® for at least 3 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).